Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2023-08-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the 12th meeting of the 5th Supervisory Board of 特一药业集团股份有限公司. It includes the Supervisory Board's review and approval of the company's 2023 semi-annual report and a special report on the use of raised funds for the same period. The document states the meeting details, voting results, and confirms compliance with relevant regulations. The document length is short (1082 characters) and it does not contain the actual semi-annual report or detailed financial statements, but rather the Supervisory Board's approval and summary of these reports. Therefore, this is not the semi-annual report itself (which would be an Interim/Quarterly Report - IR), but an announcement of the Supervisory Board's resolution regarding the report. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about the supervisory board's meeting and approvals, not the report itself or a full financial disclosure.
2023-08-28 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, asset and liability figures, shareholder information, and bond details. The document explicitly states it is a summary of the half-year report and includes substantive financial data and analysis. The length is 3058 characters, which is relatively short but contains actual financial figures and not just an announcement or a link to a report. Therefore, it is a comprehensive interim/quarterly report rather than a mere announcement or summary without data. According to the filing definitions, this fits best under 'Interim / Quarterly Report (IR)' which covers comprehensive financial reports for periods shorter than a full fiscal year with actual financial statements and substantive data. Hence, the classification is IR with high confidence. H1 2023
2023-08-28 Chinese
国浩律师（深圳）事务所关于特一药业2023年度以简易程序向特定对象发行股票的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding a specific stock issuance by 特一药业集团股份有限公司 in 2023. It extensively discusses the legal compliance, approvals, qualifications, and substantive conditions related to the company's simplified procedure private placement of shares to specific investors. The document references relevant laws, regulations, company governance, and the issuance process, indicating it is a legal opinion related to a capital raising event. It is not a financial report, earnings release, or management discussion. It is not a proxy, voting result, or AGM material. It is not a merger or acquisition document. The document is a legal opinion letter supporting a capital/financing activity, specifically a private placement of shares. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is the report itself, not just an announcement or certification, so it is not RPA or RNS.
2023-08-20 Chinese
特一药业最近一年的财务报告及其审计报告以及最近一期的财务报告
Regulatory Filings
2023-08-20 Chinese
东莞证券关于特一药业2023年度以简易程序向特定对象发行股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) related to a 2023 private placement of shares by 特一药业集团股份有限公司. It is issued by 东莞证券股份有限公司 as the sponsor and underwriter. The content includes detailed information about the securities issuance, the sponsor's commitments, internal review procedures, financial data of the issuer, shareholder structure, and legal compliance. It is a formal document supporting a capital raising event through a private placement of shares. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters), contains substantive financial and procedural details, and is not merely an announcement or a report publication notice. Therefore, it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). It is not an Annual Report, Earnings Release, or other categories related to governance or legal proceedings. Hence, the correct classification is CAP with high confidence.
2023-08-20 Chinese
特一药业2023年度以简易程序向特定对象发行股票募集说明书（申报稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度以简易程序向特定对象发行股票募集说明书" which translates to "2023 Annual Simplified Procedure Private Placement Stock Issuance Prospectus." It contains detailed information about the company's stock issuance to specific investors, including the background, purpose, pricing, share structure, risk factors, and use of proceeds. It also includes statements from the board, legal and accounting firms, and detailed financial and operational disclosures related to the issuance. This type of document is a detailed offering prospectus related to capital raising through a private placement of shares, which fits the category of Capital/Financing Update filings. It is not an annual report, earnings release, or other report types. The document length is substantial (15,000 characters), and it contains substantive financial and operational data related to the capital raising event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-08-20 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.